1,267 results on '"Ross, Merrick I."'
Search Results
2. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
3. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
4. Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
5. Neoadjuvant relatlimab and nivolumab in resectable melanoma
6. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
7. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
8. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
9. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020
10. Vascular stenting of a malignant arterial blowout as a bridge to effective systemic and regional therapy
11. Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review
12. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
13. Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options
14. Treatment of Primary Melanomas
15. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era
16. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
17. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
18. Prognostic significance of acral lentiginous histologic type in T1 melanoma
19. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
20. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features
21. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
22. Role of Immune Response, Inflammation, and Tumor Immune Response–Related Cytokines/Chemokines in Melanoma Progression
23. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
24. Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma
25. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma
26. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
27. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
28. Treatment of Primary Melanomas
29. Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options
30. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
31. Supplementary Table 3 - 4 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
32. Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
33. Supplemental Table 2. Distribution of primary vulvar melanomas with tumor thickness > 4.00 mm reported in literature. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
34. Supplementary Table 2 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
35. Supplementary Table 1 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
36. Supplementary Figure and Supplementary Tables from Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
37. CCR Translation for the Article from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
38. Supplementary Table 5 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
39. Supplementary Figures 1 - 7 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
40. Supplementary Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
41. Supplemental Figure Legend from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
42. Supplementary Table 1. Associations between clinical and histopathologic parameters are metastasis (Fisher's exact tests). from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
43. Supplementary Methods from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
44. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management.
45. Adjuvant Therapy in High-Risk, Node-Negative Melanoma.
46. Clinical Outcomes of 160 Patients with Clinically Node-Negative Merkel Cell Carcinoma after Wide Excision and Sentinel Lymph Node Biopsy
47. Neoadjuvant systemic therapy for Merkel cell carcinoma: A Tertiary Referral Center Experience
48. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker
49. Management of Sentinel-Node Metastasis in Melanoma
50. Melanoma of the Skin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.